Amgen reveals 'stable' results
29 Jul 2008
Amgen says it has shown "good stability" in its financial performance during the last quarter.
It reports total revenue was approximately $3.8 billion (£1.9 billion), which represents a one per cent increase on the figure for the same period last year.
The company states that its adjusted net income, excluding certain expenses, was around $1.2 billion - which is two per cent down on the same three months last year.
Chairman and chief executive officer Kevin Sharer comments: "Our business showed good stability through the first half of the year, giving us confidence to increase our previously issued guidance on a full-year basis."
He adds the firm is "very pleased" with data recently released from the phase-three study of postmenopausal osteoporosis treatment denosumab and expects to unveil the full results this autumn.
Amgen last week said the trial had shown that treatment with denosumab resulted in a statistically-significant reduction in the incidence of new vertebral fractures compared with placebo.
